RCEL PE Ratio & Valuation, Is RCEL Overvalued

Historical Valuation

AVITA Medical Inc (RCEL) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.28 is considered Undervalued compared with the five-year average of -3.68. The fair price of AVITA Medical Inc (RCEL) is between 77.08 to 103.06 according to relative valuation method. Compared to the current price of 4.62 USD , AVITA Medical Inc By Undervalued By 94.01%.

Relative Value

Fair Zone

77.08-103.06

Current Price：4.62

94.01%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is AVITA Medical Inc (RCEL) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

AVITA Medical Inc (RCEL) has a current Price-to-Book (P/B) ratio of -15.87. Compared to its 3-year average P/B ratio of 5.24, the current P/B ratio is approximately -402.85% higher. Relative to its 5-year average P/B ratio of 4.22, the current P/B ratio is about -476.04% higher. AVITA Medical Inc (RCEL) has a Forward Free Cash Flow (FCF) yield of approximately -34.87%. Compared to its 3-year average FCF yield of -18.72%, the current FCF yield is approximately 86.31% lower. Relative to its 5-year average FCF yield of -14.62%, the current FCF yield is about 138.45% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for RCEL competitors is 88.60, providing a benchmark for relative valuation. AVITA Medical Inc Corp (RCEL.O) exhibits a P/S ratio of 1.28, which is -98.56% above the industry average. Given its robust revenue growth of -4.30%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of RCEL increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of RCEL in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is RCEL currently overvalued or undervalued?

What is AVITA Medical Inc (RCEL) fair value?

RCEL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of AVITA Medical Inc (RCEL) is between 77.08 to 103.06 according to relative valuation method.

How does RCEL's valuation metrics compare to the industry average?

The average P/S ratio for RCEL's competitors is 88.60, providing a benchmark for relative valuation. AVITA Medical Inc Corp (RCEL) exhibits a P/S ratio of 1.28, which is -98.56% above the industry average. Given its robust revenue growth of -4.30%, this premium appears unsustainable.

What is the current P/B ratio for AVITA Medical Inc (RCEL) as of Mar 17 2026?

As of Mar 17 2026, AVITA Medical Inc (RCEL) has a P/B ratio of -15.87. This indicates that the market values RCEL at -15.87 times its book value.

What is the current FCF Yield for AVITA Medical Inc (RCEL) as of Mar 17 2026?

As of Mar 17 2026, AVITA Medical Inc (RCEL) has a FCF Yield of -34.87%. This means that for every dollar of AVITA Medical Inc's market capitalization, the company generates -34.87 cents in free cash flow.

What is the current Forward P/E ratio for AVITA Medical Inc (RCEL) as of Mar 17 2026?

As of Mar 17 2026, AVITA Medical Inc (RCEL) has a Forward P/E ratio of -2.93. This means the market is willing to pay $-2.93 for every dollar of AVITA Medical Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for AVITA Medical Inc (RCEL) as of Mar 17 2026?

As of Mar 17 2026, AVITA Medical Inc (RCEL) has a Forward P/S ratio of 1.28. This means the market is valuing RCEL at $1.28 for every dollar of expected revenue over the next 12 months.

RCEL Valuation